Literature DB >> 18565903

Nonmetastatic pancreatic cancer: many trials, little progress.

Jörg Kleeff, Helmut Friess.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18565903     DOI： 10.1200/JCO.2008.16.9326

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Pancreatic cancer-improved care achievable.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

2.  High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.

Authors:  Xianhui Xu; Yang Wang; Jinshui Chen; Hongyun Ma; Zhuo Shao; Haitao Chen; Gang Jin
Journal:  J Gastrointest Surg       Date:  2012-05-26       Impact factor: 3.452

3.  High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Lei Wang; Feng Gu; Chao-Ying Liu; Run-Jie Wang; Jiang Li; Jun-Ying Xu
Journal:  Tumour Biol       Date:  2012-12-16

Review 4.  Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.

Authors:  Ken Herrmann; Axel Walch; Benjamin Balluff; Marc Tänzer; Heinz Höfler; Bernd J Krause; Markus Schwaiger; Helmut Friess; Roland M Schmid; Matthias P A Ebert
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-03

5.  ALCAM (CD166) expression and serum levels in pancreatic cancer.

Authors:  Michael Tachezy; Hilke Zander; Andreas H Marx; Phillip R Stahl; Florian Gebauer; Jakob R Izbicki; Maximilian Bockhorn
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.